International Journal of Clinical Pharmacology & Pharmacotherapy Volume 1 (2016), Article ID 1:IJCPP-102, 2 pages
https://doi.org/10.15344/2456-3501/2016/102
https://doi.org/10.15344/2456-3501/2016/102
Commentary
Is an Inhibitor or Blocker of Inactivation of Glycogen Synthase Kinase- 3β (GSK-3β) a Reliable Agent for Cancer Chemotherapy?
References
- Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, et al. (2013) Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 49: 1027-1031 [CrossRef] [Google Scholar] [PubMed]
- Cadoo KA, Gucalp A, Traina TA (2014) Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 6: 123-133 [CrossRef] [Google Scholar] [PubMed]
- Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527 [CrossRef] [Google Scholar] [PubMed]
- McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, et al. (2014) GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5: 2881-2911 [CrossRef] [Google Scholar] [PubMed]
- Sutherland C, Leighton IA, Cohen P (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 : 15-19 [CrossRef] [PubMed]
- Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789-813 [CrossRef] [Google Scholar] [PubMed]
- Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, et al. (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1255-1266 [CrossRef] [Google Scholar] [PubMed]
- Ichimaru Y, Saito H, Uchiyama T, Metori K, Tabata K, et al. (2015) Indirubin 3'-(O-oxiran-2-ylmethyl)oxime: a novel anticancer agent. Bioorg Med Chem Lett 25: 1403-1406 [CrossRef] [Google Scholar] [PubMed]
- Yang HM, Kim HS, Park KW, You HJ, Jeon SI, et al. (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110: 301-308 [CrossRef] [Google Scholar] [PubMed]
- Funakoshi-Tago M, Shimizu T, Tago K, Nakamura M, Itoh H, et al. (2008) Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol 76: 662-671 [CrossRef] [Google Scholar] [PubMed]
- Gunn WG, Krause U, Lee N, Gregory CA (2011) Pharmaceutical inhibition of glycogen synthase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. Blood 117: 1641-1651 [CrossRef] [Google Scholar] [PubMed]
- Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, et al. (2009) Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128: e275-286 [CrossRef] [Google Scholar] [PubMed]